Tri-En Bio Advances Dermal Regeneration with FERMAGEN™ for B2B Markets

Tri-En Bio announced on the 10th that it is advancing its FERMAGEN™ series, a microbial-derived PDRN raw material, to overcome the limitations of animal-derived PDRN while enhancing safety and sustainability. This strategic move positions the company for an expanded footprint in the global B2B market, catering to the growing demand for clean beauty solutions.

FERMAGEN™ derives its potent efficacy from Tri-En Bio's proprietary manufacturing process, which utilizes Lactobacillus plantarum, a lactic acid bacterium from traditional Korean fermented foods like kimchi. By employing advanced cell disruption and purification techniques, the company achieves high-purity PDRN. This innovative approach integrates an exclusive fragmentation technology that precisely cleaves the phosphodiester bonds of nucleic acids, enhancing product consistency.

The standardized molecular size of FERMAGEN™, confirmed through electrophoresis analysis, is beneath 100 base pairs, exhibiting a uniform and densely structured profile. This contrasts significantly with typical fish-derived PDRN, which may present a broad molecular weight distribution that complicates product consistency and efficacy.

At a recent scientific conference, Tri-En Bio was honored with the 'Excellent Poster Presentation Award' for research validating FERMAGEN™'s dermal regeneration capabilities. This recognition substantiates the product’s scientific data and academic value, setting a precedent that elevates its market credibility beyond a mere conceptual ingredient.

Focusing on the extracellular matrix (ECM) reconstruction for anti-aging effects, the company underscored the critical relationship between aging skin, wrinkle formation, and the degradation of the ECM. Unlike conventional assessments of PDRN efficacy, predominantly centered on epithelial cell migration or anti-inflammatory effects, Tri-En Bio’s presentation demonstrated that FERMAGEN™ stimulates collagen and matrix synthesis—key components for structural integrity in the dermis.

The in vitro experiments simulated chronic inflammation and aging conditions by exposing normal human dermal fibroblasts to a potent inflammatory inducer, TNF-α at 10 ng/mL. The findings revealed that exposure significantly elevated the expression of the aging-related proteinase MMP-1, disrupting collagen gene expression and contributing to ECM integrity loss.

Crucially, the treatment with FERMAGEN™ led to a marked reduction in MMP-1 mRNA expression and actual protein secretion, an outcome that positions FERMAGEN™ as a formidable competitor against prevalent PDRN sources. Particularly noteworthy was its ability to upregulate mRNA expression of type I collagen (COL1A1), which was previously suppressed by TNF-α, and significantly enhance the expression of type III collagen (COL3A1), both vital for skin elasticity and firmness.

The implications of these findings suggest that FERMAGEN™ exceeds standard epidermal recovery functions, positioning it as a next-generation material with potential applications in dermal ECM regeneration and collagen synthesis. This development may lead to considerable interest from buyers and distributors looking to incorporate scientifically validated ingredients into their product lines that appeal to increasingly discerning consumers.